Bio-Rad Laboratories (NYSE:BIO) EVP Sells $348,325.34 in Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Courtney Enloe sold 902 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $386.17, for a total transaction of $348,325.34. Following the completion of the sale, the executive vice president owned 750 shares in the company, valued at $289,627.50. This represents a 54.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Bio-Rad Laboratories Stock Down 2.9%

Shares of Bio-Rad Laboratories stock traded down $11.31 on Thursday, reaching $374.69. The stock had a trading volume of 53,230 shares, compared to its average volume of 305,648. The company has a 50 day moving average price of $373.82 and a 200 day moving average price of $316.75. The company has a quick ratio of 2.37, a current ratio of 3.18 and a debt-to-equity ratio of 0.11. Bio-Rad Laboratories, Inc. has a 1 year low of $236.73 and a 1 year high of $396.23. The stock has a market capitalization of $10.02 billion, a P/E ratio of 9.87 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, November 4th. The medical research company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.23 by $0.42. The firm had revenue of $656.40 million during the quarter, compared to analyst estimates of $649.94 million. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.58%. Bio-Rad Laboratories’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.26 EPS. As a group, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 9.71 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BIO. Citigroup increased their price objective on Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Royal Bank Of Canada upped their target price on Bio-Rad Laboratories from $390.00 to $440.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Weiss Ratings upgraded Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Wells Fargo & Company boosted their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $366.67.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at $34,000. Integrated Wealth Concepts LLC acquired a new stake in Bio-Rad Laboratories during the 2nd quarter worth about $27,000. Hollencrest Capital Management purchased a new stake in Bio-Rad Laboratories during the 1st quarter valued at about $28,000. Nykredit A S purchased a new stake in Bio-Rad Laboratories during the 2nd quarter valued at about $118,000. Finally, Signaturefd LLC grew its stake in Bio-Rad Laboratories by 51.7% during the 3rd quarter. Signaturefd LLC now owns 437 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 149 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.